They described that a 11-gene signature profile, which included USP22, was capable of predicting tumor recurrence, metastasis and poor survival after cancer diagnosis in several types of cancer: prostate, lung, breast, ovarian, bladder, lymphoma, glioma, mesothelioma, neuroblastoma, mantle cell lymphoma and acute myeloid leukemia. Here, USP22 is linked to cancer.